Fig. 3
From: Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy
m6A regulators alter immune checkpoint expression in tumors. Among writers, METTL3 enhances PD-L1 expression in non-small cell lung cancer (NSCLC) and oral squamous cell carcinoma (OSCC), and augments CD80 and CD86 in DCs and macrophage, respectively. For erasers, FTO increases PD-1 and PD-L1 expression in melanoma and intrahepatic cholangiocarcinoma (ICC), respectively; FTO also ascends the expression of PD-L1, PD-L2 and LILRB4 in acute myeloid leukemia (AML). For readers, YTHDC1 escalates the expression of PD-L1 in NSCLC; YTHDF1 boosts the expression of CD80 in DCs, and descends the expression of PD-L1 in NSCLC; YTHDF2 decreases the expression of PD-L1 in ICC and NSCLC, as well as the expression of LILRB4 in AML